Multiple Myeloma: Difference between revisions

No edit summary
No edit summary
 
(25 intermediate revisions by 7 users not shown)
Line 4: Line 4:
'''Top Contributors''' - {{Special:Contributors/{{FULLPAGENAME}}}}    
'''Top Contributors''' - {{Special:Contributors/{{FULLPAGENAME}}}}    
</div>  
</div>  
== Definition/Description  ==
== Description  ==
[[File:Multiple Myeloma pic.jpg|right|frameless|400x400px]]
Multiple Myeloma (MM) is a type of [[Oncological Disorders|cancer]] formed by cancerous [[Blood|plasma]] cells (monoclonal proliferation of plasma cells). To date, multiple myeloma is an incurable disease with a poor prognosis. Most individuals die within 1 to 3 years after the diagnosis is made.<ref name="Differential text" />


Multiple myeloma is a type of cancer formed by cancerous plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the body's immune system. &nbsp; &nbsp; [[Image:MRI bones.jpg|frame|right|75x75px|FDG PET (fluorodeoxyglucose positron emission tomography) scan of a patient with multiple myeloma with severe diffuse and focal disease]]&nbsp;
The [[Immune System|immune system]]
* Made up of several types of cells that work together to fight [[Infectious Disease|infections]].
* Lymph cells (called lymphocytes) are the main type of cell in the immune system.
* There are 2 types of lymph cells: T cells and B cells.
* When B cells respond to an infection, they change into plasma cells. Plasma cells, also called plasma B cells, are white blood cells that originate in the bone marrow and secrete large quantities of proteins called antibodies in response to being presented specific substances called antigens. &nbsp;
* When plasma cells grow out of control, they can form a tumor, usually in the [[bone]] marrow.
* This type of tumor is called a myeloma, and if there are many tumors they are called multiple myeloma.<ref name="American Cancer Society">American Cancer Society website. 2010. Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_2_1x_What_Is_Multiple_Myeloma.asp?sitearea=. Accessed April 4, 2010.</ref>
* Tumors of this type initially affect the bones and bone marrow of the vertebrae, [[ribs]], [[Skull|skul]]<nowiki/>l, [[pelvis]], and [[femur]]. These regions are most often affected because of their high concentrations of bone marrow.<span style="">&nbsp; </span>The progression of this disease can cause damage to the kidney, lead to recurrent infections, and often affects the nervous system <ref name="Differential text">3. Goodman C, Snyder T. Differential Diagnosis for Physical Therapists: Screening for Referral. St. Louis: Saunders Elsevier; 2007.</ref>.<span style="">&nbsp;</span>
[[File:Multiple Myeloma Osteolytic Lesions.jpg|alt=|thumb|Multiple Myeloma Osteolytic Lesions]]


The immune system is made up of several types of cells that work together to fight infections. Lymph cells (called lymphocytes) are the main type of cell in the immune system. There are 2 types of lymph cells: T cells and B cells.  
== Etiology  ==
The exact etiology of MM is unknown.
* There is evidence that suggests genetic abnormalities in oncogenes such as CMYC, NRAS, and KRAS may play a role in the development of plasma cell proliferation.
* MM has also been associated with other factors such as drinking [[Alcoholism|alcohol]], [[obesity]], environmental causes such as insecticides, organic solvents, and [[Radiation Side Effects and Syndromes|radiation]] exposure.<ref name=":0">Albagoush SA, Azevedo AM. [https://www.ncbi.nlm.nih.gov/books/NBK534764/ Cancer, Multiple Myeloma.]Available from: https://www.ncbi.nlm.nih.gov/books/NBK534764/ (last accessed 14.7.2020)</ref>


When B cells respond to an infection, they change into plasma cells. The plasma cells are mainly in the bone marrow—the soft, inner part of some bones. The plasma cells make proteins called antibodies that attack and help kill germs.  
== Epidemiology ==
* MM represents 1.8% of all new cancer cases in the United States.  
* Occurs predominantly in the geriatric population with a median age at diagnosis of about 70 years.  
* The number of cases diagnosed annually is expected almost to double in 20 years.
* It has a male-to-female ratio of 3 to 2 and is more common among African-Americans<ref name=":0" />.  


When plasma cells grow out of control, they can form a tumor, usually in the bone marrow. This type of tumor is called a myeloma, and if there are many tumors they are called multiple myeloma.<ref name="American Cancer Society">American Cancer Society website. 2010. Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_2_1x_What_Is_Multiple_Myeloma.asp?sitearea=. Accessed April 4, 2010.</ref>
== Presentation ==
The presentation can vary from asymptomatic to severely ill.  


<br>
* Usually, the patient is an [[Older People - An Introduction|older adult]] complaining of constitutional symptoms such as fatigue, weight loss, and bone pain, particularly in the back and chest. 


According to Goodman and Fuller, tumors of this type initially affect the bones and bone marrow of the vertebrae, ribs, skull, pelvis, and femur. These regions are most often affected because of their high concentrations of bone marrow.<span style="">&nbsp; </span>The progression of this disease can cause damage to the kidney, lead to recurrent infections, and often affects the nervous system <ref name="Differential text">3. Goodman C, Snyder T. Differential Diagnosis for Physical Therapists: Screening for Referral. St. Louis: Saunders Elsevier; 2007.</ref>. <span style="">&nbsp;</span>To date, multiple myeloma is an incurable disease with a poor prognosis. Most individuals die within 1 to 3 years after the diagnosis is made <ref name="Pathology text">Goodman C, Fuller K. Pathology: Implications for the Physical Therapist. St. Louis: Saunders Elsevier; 2009.</ref>.<br>
* Pathological [[Fracture|fractures]] and vertebral collapse lead to a reduction in height, spinal cord compression, [[Radiculopathy|radicular]] pain or [[Thoracic Hyperkyphosis|kyphosis]]. 
*[[Anaemia]] usually causes pallor, palpitation and worsening of previous heart failure or angina.
* Renal failure (acute and/or chronic) can lead to edema, acidosis, and electrolyte disturbances. [[Hypercalcemia]], [[dehydration]], and hypergammaglobulinemia further aggravate renal injury and may lead to confusion and coma.
* Secondary [[amyloidosis]] can cause peripheral neuropathy and carpal tunnel syndrome.
* Those with hyperviscosity may have symptoms like paresthesia, headache, dyspnea, nasal bleeding, blurry vision.
* MM patients are more prone to infections, mostly pneumonia, and pyelonephritis. 
Physical examination. Variable depending on the extent of disease, usually include
* Pallor, tachycardia, tachypnea, petechiae or ecchymoses, bone tenderness, edema or signs of dehydration and central or peripheral neurologic signs.  
* Fundoscopic signs include exudative macular detachment, retinal hemorrhage or cotton-wool spots. Carpal tunnel syndrome may cause positive Tinel and Phalen signs<ref name=":0" />
[[File:Multiple myeloma.jpg|alt=|thumb|CT, osteoblastic lesions of multiple myeloma.]]


<br>
== Radiographic features ==
Radiographic features - Include:
* Numerous well circumscribed, lytic bone lesions
* Punched out lucencies
* Raindrop skull
* Endosteal scalloping
* Generalised [[osteopenia]]
== Treatment / Management  ==
# Initial therapy of MM varies depending on disease risk stratification and functional status, which will help determine transplant eligibility. Patients who are
* Fit for transplant typically receive induction therapy for a few months to decrease the tumor burden, followed by peripheral blood stem cell mobilization and harvesting, and finally, an autologous transplant.
* Transplant-ineligible patients, common regimens include lenalidomide and dexamethasone, bortezomib and dexamethasone, melphalan/prednisone/bortezomib, and other bortezomib-based regimens. Novel agents such as oral proteasome inhibitors have shown promising results.
2. For symptomatic anemia, blood transfusion and sometimes erythropoiesis-stimulating agents are used.


[Image courtesy of&nbsp;[http://www.uams.edu/radiology/info/clinical/pet/images.asp University of Arkansas for Medical Sciences]]
3. Plasmapheresis is used for the hyperviscosity syndrome.


<br>
4. [[Hypercalcemia]] and renal failure treatments include hydration, glucocorticoids, bisphosphonates, calcitonin, and hemodialysis.


== Prevalence<br>  ==
5. MM patients are more prone to infections. Prophylactic measures include yearly influenza [[Vaccines|vaccine]], pneumococcal vaccine at the time of diagnosis, prophylactic antibiotics and hematopoietic growth factors during the first few months of [[Chemotherapy Side Effects and Syndromes|chemotherapy]] induction, intravenous immunoglobulin for patients with recurrent infections.


*20,580 new cases of multiple myeloma (about 11,190 in&nbsp;men and about 8,730 in women)
6.Bone [[Pain Behaviours|pain]] usually requires [[opioids]] for control.


*10,580 deaths from multiple myeloma
7. [[Spinal cord anatomy|Spinal cord]] compression by vertebral fracture or plasmacytoma is a medical emergency and should be managed aggressively with radiotherapy and orthopedic consultation.s into your bloodstream so they can be collected and transplanted back into the body.<ref name=":0" />
*In the United States, the lifetime risk of getting multiple myeloma is 1 in 161.


<br>  
== Diagnostic Procedures  ==
[[File:Multiple Myeloma Biopsy.jpg|right|frameless]]
According to the National Comprehensive Cancer Network (NCCN) criteria, MM is defined as smoldering (asymptomatic) or active (symptomatic). Major and minor criteria were created to distinguish multiple myeloma from asymptomatic myeloma and monoclonal gammopathies of undetermined significance (MGUS). 
* The Evaluation of the patient is an involved process and beyond the scope of this article<ref name=":0" />.
* Diagnosis is not always obvious, especially in older patients, given their increased comorbidities. MM should always be suspected in an elderly patient with normocytic anemia, bone pain and evidence of renal dysfunction.


Scientists have found a few risk factors that may make a person more likely to get multiple myeloma. These are the known risk factors for multiple myeloma:
== Prognosis ==
 
* Older patients will often have serious concomitant diseases affecting survival.
'''Age and gender:<span class="apple-converted-space">&nbsp;</span>'''Age is the biggest risk factor for multiple myeloma. Very few cases are found in people younger than 35. Most people with this cancer are over 65 years old. Men are slightly more likely to get multiple myeloma than women.
* Younger patients have less treatment-related morbidity, and consequently, fare better.
 
* In 2003, with high-dose therapy followed by autologous stem cell transplantation, median survival was estimated to be approximately 4.5 years, compared to a median of approximately 3.5 years with standard therapy.  
'''Race:&nbsp;'''Multiple myeloma is almost twice as common among black Americans as white Americans. The reason is not known.<ref name="American Cancer Society" />
* The overall survival in MM has improved over the last decade due to more accurate diagnosis and risk stratification, a better understanding of how toxicity and frailty can affect prognosis, the discovery of novel agents, and advances in supportive care during the post-transplant period.<ref name=":0" />  
 
* Overall, the 5-year survival rate is around 35%
== Characteristics/Clinical Presentation  ==
 
Multiple Myeloma presence and pain <ref name="Differential text" />:
 
*Location: skeletal pain, especially in the spine, sternum, rib,&nbsp;leg, or arm
 
*Referral: according to the location of the tumor
*Description: sharp, knife like
*Intensity: moderate to severe
*Duration: intermittent, progressing to constant
*Associated signs and symptoms:
**Skeletal – [http://www.mayoclinic.com/health/hypercalcemia/DS00976 Hypercalcemia]: symptoms include dehydration (vomiting), polyuria, confusion, loss of appetite, constipation
**Bone destruction with spontaneous bone fracture
**Neurologic – [http://www.mayoclinic.com/health/carpal-tunnel-syndrome/DS00326 Carpal tunnel syndrome]; back pain with radicular symptoms; spinal cord compression (motor or sensory loss, bowel/bladder dysfunction, paraplegia)
 
When to see a doctor, according to Mayoclinic.com:
 
If you're persistently more tired than you used to be, you've lost weight, and you experience bone pain, repeated infections, loss of appetite, excessive thirst and urination, persistent nausea, increased constipation, or weakness or numbness in your legs, your signs and symptoms may indicate multiple myeloma or other serious disease. See your doctor to determine the underlying cause <ref name="Mayo clinic">Mayoclinic.com. 2010. Available at: http://www.mayoclinic.com/health/multiple-myeloma/DS00415. Accessed March 1, 2010.</ref>.
 
== Associated Co-morbidities  ==
 
Excerpt from the International Myeloma Foundation<ref name="Myeloma foundation">[http://myeloma.org/ArticlePage.action?tabId=1&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;menuId=161&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;articleId=2732&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;aTab=-1&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;gParentType=menuitem&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;gParentId=161&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;parentIndexPageId=52&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;parentCategoryId=443 International Myeloma Foundation website]. Accessed March 3, 2010.</ref>
 
'''TABLE 2: MEDICAL PROBLEMS RELATED TO MYELOMA'''&nbsp;
 
[[Image:TABLE 2 MEDICAL PROBLEMS RELATED TO MYELOMA.jpg|Image:TABLE_2_MEDICAL_PROBLEMS_RELATED_TO_MYELOMA.jpg]]
 
== Medications<ref name="drugs.com">Drugs.com. 2010. Available at: http://www.drugs.com/condition/multiple-myeloma.html. Accessed March 3, 2010.</ref>  ==
 
*Cytoxan is an antineoplastic. It works by stopping or slowing the growth or spread of certain cancer cells.
*Revlimid affects the immune system. It helps promote immune responses to prevent inflammation in the body.
*Adriamycin is an antineoplastic antibiotic. It works by killing cancer cells.
*Velcade interferes with the growth of some cancer cells and keeps them from spreading in your body.  
*Thalomid affects the immune system. It helps promote immune responses to prevent inflammation in the body. It is used together with another medicine called Dexamethasone to treat multiple myeloma (bone marrow cancer).
*Doxil is an antineoplastic antibiotic. It works by killing cancer cells.
*Alkeran is an alkylating agent. It works by destroying resting and rapidly dividing tumor cells in certain types of cancer.
*Oncovin (Vincristine) is cancer medication that interferes with the growth of cancer cells and slows their spread in the body.
*Mozobil works by helping your bone marrow release stem cells into your bloodstream so they can be collected and transplanted back into the body.
*Neosar is an antineoplastic. It works by stopping or slowing the growth or spread of certain cancer cells.
*Cyclophosphamide is a cancer (chemotherapeutic) medication. Cyclophosphamide interferes with the growth of cancer cells and slows their growth and spread in the body.
*Cyclophosphamide is a cancer (chemotherapeutic) medication. Cyclophosphamide interferes with the growth of cancer cells and slows their growth and spread in the body.
*BiCNU is an antineoplastic. It works by blocking the growth of cancer cells.
*Bisphosphonates can be used to prevent fractures.
 
== Diagnostic Tests/Lab Tests/Lab Values  ==
 
[[Image:Bone marrow sample.jpg|frame|This bone marrow tissue sample shows myeloma cells (bluish-stained cells). These cells crowd out normal bone marrow cells]]Blood tests can help diagnose this disease. They may include <ref name="Google MM">A.D.A.M. Google Health: Multiple Myeloma. 2010. Available at: https://health.google.com/health/ref/Multiple+myeloma. Accessed March 1, 2010.</ref>  
 
*Blood chemistry (CHEM 20) may show increased levels of calcium, total protein, and abnormal kidney function
*Complete blood count (CBC) reveals low numbers of red and white blood cells and platelets
*Serum protein electropheresis (SPEP)
*Urine protein electrophoresis (UPEP) or Bence-Jonesprotein analysis
*Quantitative immunoglobulins (nephelometry)
 
<br> [Image courtesy of [http://www.mayoclinic.com/health/multiple-myeloma/DS00415 Mayo Foundation for Medical Research]
 
Bone x-rays show fractures or hollowed out areas of bone. If this type of cancer is suspected, a bone marrow biopsy might be performed in order diagnose.
 
Major and minor criteria were created to distinguish multiple myeloma from asymptomatic myeloma and monoclonal gammopathies of undetermined significance (MGUS). Individuals must have at least one major and one minor or three minor criteria to be diagnosed with multiple myeloma.
 
Criteria for the Diagnosis of Multiple Myeloma <ref name="Pathology text" />: [[Image:Multiple myeloma diagnostic criteria.jpg|Image:Multiple_myeloma_diagnostic_criteria.jpg]]
 
== Causes  ==
 
The exact cause of multiple myeloma is unknown. It has been reported that the beginning of multiple myeloma begins with the presence and multiplication of an abnormal plasma cell in the bone marrow. Exposure to ionizing radiation and occupational hazards (i.e. petroleum, leather, lumber, and agricultural industries) may be linked to the presence of this abnormal plasma cell formation. Abnormal cells do not behave as normal cells do, with maturation and death. These abnormal cells accumulate and thus eventually overwhelm the number and production of healthy cells. Statistically, in healthy bone marrow less than 5 percent of the cells are plasma cells. Individuals with multiple myeloma display a presence of more than 10 percent of the cells in bone marrow being plasma cells. Multiple myeloma is a malignancy that increases the rate of abnormal cell division. Uncontrolled plasma cell growth can damage bones and surrounding tissue. It can also interfere with your immune system's ability to fight infections by inhibiting your body's production of normal antibodies <ref name="Pathology text" /><ref name="Mayo clinic" />.


== Systemic Involvement  ==
== Systemic Involvement  ==
 
[[File:National-cancer-institute-0YBIMOqQzt0-unsplash.jpg|right|frameless]]
Multiple myeloma systemic involvement list excerpt from Goodman and Snyder <ref name="Differential text" />:  
 
'''Immune System:'''  
'''Immune System:'''  
*Recurrent bacterial infections (especially pneumococcal pneumonias)
*Recurrent bacterial infections (especially pneumococcal pneumonias)


Line 136: Line 109:
**Carpal tunnel syndrome  
**Carpal tunnel syndrome  
**Back pain with radicular symptoms  
**Back pain with radicular symptoms  
**Spinal cord compression (motor or sensory loss, bowel/bladder dysfunction, paraplegia)
**Spinal cord compression (motor or sensory loss, bowel/bladder dysfunction, paraplegia)<ref name="Differential text" />
 
== Medical Management (current best evidence)  ==
 
The most advantageous treatment techniques according to The American Cancer Society as of 2009<ref name="American Cancer Society" />:
 
'''Chemotherapy and other drugs'''
 
Chemotherapy (chemo) is the use of drugs to kill or control the cancer cells. These drugs are either taken by mouth as a pill or injected into a vein or a muscle. The drugs enter the blood and reach throughout the body. This treatment is useful for cancers such as multiple myeloma that often spread widely. The drugs can be used alone or in combination.
 
The choice and dose of the drugs depend on many factors, such as: the stage of the cancer the patient's age the health of the patient's kidneys whether a stem cell transplant is planned (If a stem cell transplant is planned, most doctors avoid using drugs that can damage the bone marrow)
 
Chemo can cause some side effects. These side effects will depend on the type of drugs given, the amount taken, and how long the treatment lasts. Side effects could include the following: hair loss (hair grows back after treatment), mouth sores, loss of appetite nausea and vomiting low blood counts.
 
Low blood counts can cause: increased chance of infection (from a shortage of white blood cells), easy bruising or bleeding (from a shortage of platelets) and tiredness (from a shortage of red blood cells)
 
Most side effects go away after treatment ends. But some chemo drugs can cause long-term damage to certain organs, like the heart or kidneys. These risks of the drugs are balanced against their benefits. And the health of these organs is carefully watched during treatment. If serious organ damage starts, doctors will switch to a different drug.
 
Your doctor or nurse can suggest steps to ease some side effects. For example, there are drugs that can prevent or reduce nausea and vomiting.
 
'''Bisphosphonates'''
 
Myeloma cells can cause bone to dissolve. This can lead to weakness and broken bones. Drugs called bisphosphonates can slow down this process. Treatment with a bisphosphonate helps prevent further bone damage in multiple myeloma patients.
 
Bisphosphonate treatment does have a rare but serious side effect. Some patients complain of pain in the jaw and doctors find that part of the bone of the upper or lower jaw bone has died. This can lead to loss of teeth in that area. Infections of the jaw bone may also develop. Doctors don't know why this happens or how best to prevent it. The only factor that doctors have found that increases the risk of this problem is having jaw surgery or having a tooth removed. These should be avoided during treatment. Many doctors recommend that patients have a dental check-up and have any tooth or jaw problems treated before they start bisphosphonate treatment.
 
'''Radiation therapy'''
 
Radiation therapy is the use of high-energy x-rays to kill cancer cells. It may be used to treat areas of damaged bone that have not responded to chemo and are causing pain. It is also the most common treatment for solitary plasmacytomas.
 
Myeloma can weaken back bones so badly that the bones collapse and put pressure on the spinal cord and spinal nerves. This can cause sudden numbness or tingling, sudden weakness of leg muscles, or sudden problems with urinating or moving the bowels. This is a medical emergency that needs to be treated right away. The treatment may involve radiation therapy and/or surgery.
 
The type of radiation treatment used in treating multiple myeloma is called external beam radiation therapy. This means the radiation is given from outside the body. Having this treatment is much like getting an x-ray. But the treatment lasts longer and is usually done several times a week for many weeks.
 
'''Surgery'''
 
Surgery is not often used to treat multiple myeloma. As noted above, emergency surgery may be needed when the spinal cord is pinched. Surgery to attach metal rods or plates can help support weight-bearing bones in the spine or legs. This may be done to prevent bones from breaking.
 
'''Biologic therapy'''
 
Biologic therapy (immunotherapy) is treatment that uses proteins that are normally found in the body to fight disease, even cancer. Interferon is a hormone-like substance made by some white blood cells and bone marrow cells. Interferon slows growth of myeloma cells. A man-made version of this substance is sometimes used along with chemo. But interferon has mostly helped patients who have had chemo and are in remission. Interferon seems to make remission last longer.
 
Side effects of this drug include tiredness and flu-like symptoms. Some patients have trouble dealing with these symptoms. But overall, the benefits of longer remission and fewer symptoms usually outweigh these side effects.
 
'''Stem cell transplant'''
 
This has become the standard treatment for younger myeloma patients in good health. It allows higher doses of chemo to be used. Many centers are using this treatment for patients up to age 70. Several studies have shown that this treatment increases how long patients live compared to standard chemo.
 
The first step in the process is to lower the amount of cancer in a patient's body. This is done with certain chemo drugs. At the same time, blood-forming cells are taken from the patient's (or a donor's) blood or bone marrow. The cells (called stem cells) are then frozen.
 
The patient then gets high-dose chemo to kill any remaining myeloma cells. The treatment also destroys all the bone marrow stem cells. This would normally kill the patient. But the frozen stem cells can be given to the patient after chemo. They are given into the bloodstream through an IV. The stem cells travel to the bone marrow where they begin to make new blood cells.
 
'''Autologous transplant'''
 
If the patient's own stem cells are used, it is called an autologous transplant. These transplants are fairly safe and have a low risk of serious complications. Because of this, they can be used for older patients. But it is hard to kill all the myeloma cells with high-dose chemo. Most patients who have autologous transplants will have their myeloma return at some point. Although a few of these patients will be free of myeloma for a long time, this procedure doesn't cure the disease. Some doctors now recommend getting a second stem cell transplant (called a tandem transplant) within a year. While this might lengthen survival time, it can be hard on patients, and more research on this approach is needed.
 
The high doses of chemo used in autologous transplant can cause many problems. Many patients have high fevers from infections. These are treated with IV antibiotics. Another common problem is mouth sores, which can be very painful. Morphine may be given to reduce the pain. The chemo also kills cells in the intestines, which may lead to cramps and diarrhea. Since the bone marrow is unable to make blood cells, transfusions of red blood cells and platelets are often needed. When the new stem cells start making new blood cells, the transfusions are no longer needed.
 
'''Allogeneic transplant'''
 
When stem cells from a donor are used, the transplant is referred to as allogeneic. The donor is usually a close relative. Less often, it is an unrelated person whose tissue type closely matches that of the patient. Allogeneic transplants carry a higher risk of severe complications, even death. But they may produce longer remissions. This is because the donor's immune system cells may help to destroy the myeloma cells. Allogeneic transplants are not used often in myeloma patients. There are 2 reasons for this: First, the patient must be fairly young and healthy to withstand the side effects of transplant--most myeloma patients are elderly. Second, a donor's tissue type must match the patient's. Such matches can be hard to find.
 
Mini-transplant: Some allogeneic transplants use low doses of certain kinds of chemo drugs to allow the transplanted stem cells to "take" without all the side effects of high doses. This is sometimes called a "mini-transplant" or a non-myeloablative transplant. This type of transplant allows the treatment to be done on older patients. Although the myeloma hasn't been destroyed by the low-dose chemo, the transplanted stem cells are expected to act against the myeloma cells and destroy them.
 
'''Plasmapheresis'''
 
Plasmapheresis is helpful when build-up of myeloma proteins thickens the blood and slows circulation. While this treatment can relieve some symptoms, it does not kill the myeloma cells.
 
For this treatment, a machine removes blood from a vein. The blood cells are then separated from the plasma (the liquid part of the blood) and returned into another vein. The large amounts of abnormal proteins released by the myeloma cells are in the plasma. The plasma is discarded and replaced with a salt solution and blood proteins from donors.
 
== Physical Therapy Management (current best evidence)  ==
 
Therapists can assist individuals with multiple myeloma to manage both the disease and treatment-related symptoms, improve overall quality of life, and prevent further complications associated with decreased activity and exercise.&nbsp;[[Image:Pt treatment.jpg|frame]]<br>
 
The therapist may play an important role in various stages of the progression of this disease, including prevention and management of skeletal muscle wasting, cancer-related fatigue, and pathologic fractures. Individualized exercise programs for individuals receiving aggressive treatment for multiple myeloma may be effective for decreasing fatigue and mood disturbance and for improving sleep.&nbsp;
 
The guidelines suggest referral to physical therapy for fitness assessment and exercise recommendations with emphasis on getting clients to gradually increase their activity level to avoid sustaining an injury or becoming discouraged. Short, low-intensity exercise programs may be helpful at first. The key is to get the individual to implement and maintain the program.
 
The therapist’s ability the implement falls assessment and prevention programs can be a life-saving intervention for the individual at risk for pathologic fractures. Exercise interventions to improve function and decrease muscle wasting and cancer-related fatigue during and after cancer treatment for multiple myeloma have been shown effective.<ref name="Pathology text" />  
 
<br>
 
[Image courtesy of [http://www.healthline.com/images/staywell/37313.jpg Healthline.com]]


== Physical Therapy Management  ==
[[File:Strengthing exercise for old people .jpg|right|frameless]]
Therapists can assist individuals with multiple myeloma to manage both the disease and treatment-related symptoms, improve overall [[Quality of Life|quality of life]], and prevent further complications associated with decreased activity and [[Exercise -Therapeutic|exercise]].&nbsp;
* An important role in various stages of the progression of this disease includes prevention and management of: skeletal [[Muscle Function: Effects of Aging|muscle wasting]]; cancer-related fatigue, and pathologic [[fracture]]<nowiki/>s. Exercise interventions to improve function and decrease muscle wasting and cancer-related fatigue during and after cancer treatment for multiple myeloma have been shown effective.<ref name="Pathology text" />
* [[Adherence to Home Exercise Programs|Individualized exercise programs]] for individuals receiving aggressive treatment for multiple myeloma may be effective for decreasing fatigue and mood disturbance and for improving sleep.&nbsp;
* The guidelines suggest referral to physical therapy: [[Physical Activity|Fitness]] assessment and exercise recommendations (emphasis on getting clients to gradually increase their activity level to avoid sustaining an injury or becoming discouraged). Short, low-intensity exercise programs may be helpful at first. 
* Implementation of a  [[falls]] prevention programs can be a life-saving intervention for the individual at risk for pathologic fractures.<ref name="Pathology text">Goodman C, Fuller K. Pathology: Implications for the Physical Therapist. St. Louis: Saunders Elsevier; 2009.</ref>
== Differential Diagnosis  ==
== Differential Diagnosis  ==


Line 230: Line 128:


== Case Reports  ==
== Case Reports  ==
* Multiple myeloma and engine exhausts, fresh wood, and creosote: A case-referent study<ref name="journal of industrial medicine">Flodin U, Fredriksson M, and Persson B. Multiple myeloma and engine exhausts, fresh wood, and creosote: A case-referent study. American Journal of Industrial Medicine. Jan 2007. Volume 12; 5, 519-529.</ref>&nbsp;[view article in ''[http://www3.interscience.wiley.com/journal/114061290/abstract?CRETRY=1&SRETRY=0 American Journal of Industrial Medicine]'']
* Occupational and other environmental factors and multiple myeloma: a population based case-control study<ref name="occupational and environmental medicine">Eriksson M and Karlsson M. Occupational and other environmental factors and multiple myeloma: a population based case-control study. Br J Ind Med 1992;49:95-103.</ref> [view article in&nbsp;''[http://oem.bmj.com/content/49/2/95 Occupational and Environmental]]''
* <span style="">Multiple myeloma: A review of the epidemiologic literature<ref name="international journal of cancer">Alexander D, et. al. Multiple myeloma: A review of the epidemiologic literature. International Journal of Cancer. 2007. Volume 120; 12.</ref>&nbsp;[view article in ''[http://www3.interscience.wiley.com/cgi-bin/fulltext/114205266/PDFSTART International Journal of Cancer]'']</span>
* Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study<ref name="international journal of cancer 2">Landgren O, et. al. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study. Int. J. Cancer. 2006. Volume 118, 3095–3098.</ref> [view article in ''[http://www3.interscience.wiley.com/cgi-bin/fulltext/112224626/PDFSTART International Journal of Cancer]]''<br>


Multiple myeloma and engine exhausts, fresh wood, and creosote: A case-referent study<ref name="journal of industrial medicine">Flodin U, Fredriksson M, and Persson B. Multiple myeloma and engine exhausts, fresh wood, and creosote: A case-referent study. American Journal of Industrial Medicine. Jan 2007. Volume 12; 5, 519-529.</ref>&nbsp;[view article in ''[http://www3.interscience.wiley.com/journal/114061290/abstract?CRETRY=1&SRETRY=0 American Journal of Industrial Medicine]'']
== Resources   ==
 
Occupational and other environmental factors and multiple myeloma: a population based case-control study<ref name="occupational and environmental medicine">Eriksson M and Karlsson M. Occupational and other environmental factors and multiple myeloma: a population based case-control study. Br J Ind Med 1992;49:95-103.</ref> [view article in&nbsp;''[http://oem.bmj.com/content/49/2/95 Occupational and Environmental]]''
 
<span style="">Multiple myeloma: A review of the epidemiologic literature<ref name="international journal of cancer">Alexander D, et. al. Multiple myeloma: A review of the epidemiologic literature. International Journal of Cancer. 2007. Volume 120; 12.</ref>&nbsp;[view article in ''[http://www3.interscience.wiley.com/cgi-bin/fulltext/114205266/PDFSTART International Journal of Cancer]'']</span>
 
<br>
 
Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study<ref name="international journal of cancer 2">Landgren O, et. al. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study. Int. J. Cancer. 2006. Volume 118, 3095–3098.</ref> [view article in ''[http://www3.interscience.wiley.com/cgi-bin/fulltext/112224626/PDFSTART International Journal of Cancer]]''<br>
 
== Resources <br>  ==


*Multiple Myeloma Research Foundation: [http://www.multiplemyeloma.org/ http://www.multiplemyeloma.org/]
*Multiple Myeloma Research Foundation: http://www.multiplemyeloma.org/  
*American Cancer Society: [http://www.cancer.org/docroot/home/index.asp?gclid=CNrsxv-386ACFWV75QodU1XYxQ http://www.cancer.org]  
*American Cancer Society: [http://www.cancer.org/docroot/home/index.asp?gclid=CNrsxv-386ACFWV75QodU1XYxQ http://www.cancer.org]  
*International Myeloma Foundation: [http://myeloma.org/Main.action http://myeloma.org]  
*International Myeloma Foundation: [http://myeloma.org/Main.action http://myeloma.org]  
*National Cancer Institute:&nbsp;[http://www.cancer.gov/ http://www.cancer.gov/]
*National Cancer Institute:&nbsp;http://www.cancer.gov/


== Recent Related Research (from [http://www.ncbi.nlm.nih.gov/pubmed/ Pubmed])  ==
<div class="researchbox">
<rss>http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=10GmkCX3grCLH8eksBG6LIElcGpCVQrP0FR7XH1B4Qb63bykb_|charset=UTF-8|short|max=10</rss>
</div>
== References  ==
== References  ==


<references />  
<references />  


[[Category:Oncology]] [[Category:Bellarmine_Student_Project]] [[Category:Videos]]
[[Category:Oncology]]  
[[Category:Bellarmine_Student_Project]]

Latest revision as of 07:07, 18 September 2022

Original Editors - Jill Jones from Bellarmine University's Pathophysiology of Complex Patient Problems project.

Top Contributors - Jill Jones, Admin, Lucinda hampton, Scott Buxton, Elaine Lonnemann, Nikhil Benhur Abburi, Johnathan Fahrner, Kim Jackson, 127.0.0.1, Wendy Walker, WikiSysop and Vidya Acharya  

Description[edit | edit source]

Multiple Myeloma pic.jpg

Multiple Myeloma (MM) is a type of cancer formed by cancerous plasma cells (monoclonal proliferation of plasma cells). To date, multiple myeloma is an incurable disease with a poor prognosis. Most individuals die within 1 to 3 years after the diagnosis is made.[1]

The immune system

  • Made up of several types of cells that work together to fight infections.
  • Lymph cells (called lymphocytes) are the main type of cell in the immune system.
  • There are 2 types of lymph cells: T cells and B cells.
  • When B cells respond to an infection, they change into plasma cells. Plasma cells, also called plasma B cells, are white blood cells that originate in the bone marrow and secrete large quantities of proteins called antibodies in response to being presented specific substances called antigens.  
  • When plasma cells grow out of control, they can form a tumor, usually in the bone marrow.
  • This type of tumor is called a myeloma, and if there are many tumors they are called multiple myeloma.[2]
  • Tumors of this type initially affect the bones and bone marrow of the vertebrae, ribs, skull, pelvis, and femur. These regions are most often affected because of their high concentrations of bone marrow.  The progression of this disease can cause damage to the kidney, lead to recurrent infections, and often affects the nervous system [1]. 
Multiple Myeloma Osteolytic Lesions

Etiology[edit | edit source]

The exact etiology of MM is unknown.

  • There is evidence that suggests genetic abnormalities in oncogenes such as CMYC, NRAS, and KRAS may play a role in the development of plasma cell proliferation.
  • MM has also been associated with other factors such as drinking alcohol, obesity, environmental causes such as insecticides, organic solvents, and radiation exposure.[3]

Epidemiology[edit | edit source]

  • MM represents 1.8% of all new cancer cases in the United States.
  • Occurs predominantly in the geriatric population with a median age at diagnosis of about 70 years.
  • The number of cases diagnosed annually is expected almost to double in 20 years.
  • It has a male-to-female ratio of 3 to 2 and is more common among African-Americans[3].

Presentation[edit | edit source]

The presentation can vary from asymptomatic to severely ill.

  • Usually, the patient is an older adult complaining of constitutional symptoms such as fatigue, weight loss, and bone pain, particularly in the back and chest. 
  • Pathological fractures and vertebral collapse lead to a reduction in height, spinal cord compression, radicular pain or kyphosis. 
  • Anaemia usually causes pallor, palpitation and worsening of previous heart failure or angina.
  • Renal failure (acute and/or chronic) can lead to edema, acidosis, and electrolyte disturbances. Hypercalcemia, dehydration, and hypergammaglobulinemia further aggravate renal injury and may lead to confusion and coma.
  • Secondary amyloidosis can cause peripheral neuropathy and carpal tunnel syndrome.
  • Those with hyperviscosity may have symptoms like paresthesia, headache, dyspnea, nasal bleeding, blurry vision.
  • MM patients are more prone to infections, mostly pneumonia, and pyelonephritis. 

Physical examination. Variable depending on the extent of disease, usually include

  • Pallor, tachycardia, tachypnea, petechiae or ecchymoses, bone tenderness, edema or signs of dehydration and central or peripheral neurologic signs.
  • Fundoscopic signs include exudative macular detachment, retinal hemorrhage or cotton-wool spots. Carpal tunnel syndrome may cause positive Tinel and Phalen signs[3]
CT, osteoblastic lesions of multiple myeloma.

Radiographic features[edit | edit source]

Radiographic features - Include:

  • Numerous well circumscribed, lytic bone lesions
  • Punched out lucencies
  • Raindrop skull
  • Endosteal scalloping
  • Generalised osteopenia

Treatment / Management[edit | edit source]

  1. Initial therapy of MM varies depending on disease risk stratification and functional status, which will help determine transplant eligibility. Patients who are
  • Fit for transplant typically receive induction therapy for a few months to decrease the tumor burden, followed by peripheral blood stem cell mobilization and harvesting, and finally, an autologous transplant.
  • Transplant-ineligible patients, common regimens include lenalidomide and dexamethasone, bortezomib and dexamethasone, melphalan/prednisone/bortezomib, and other bortezomib-based regimens. Novel agents such as oral proteasome inhibitors have shown promising results.

2. For symptomatic anemia, blood transfusion and sometimes erythropoiesis-stimulating agents are used.

3. Plasmapheresis is used for the hyperviscosity syndrome.

4. Hypercalcemia and renal failure treatments include hydration, glucocorticoids, bisphosphonates, calcitonin, and hemodialysis.

5. MM patients are more prone to infections. Prophylactic measures include yearly influenza vaccine, pneumococcal vaccine at the time of diagnosis, prophylactic antibiotics and hematopoietic growth factors during the first few months of chemotherapy induction, intravenous immunoglobulin for patients with recurrent infections.

6.Bone pain usually requires opioids for control.

7. Spinal cord compression by vertebral fracture or plasmacytoma is a medical emergency and should be managed aggressively with radiotherapy and orthopedic consultation.s into your bloodstream so they can be collected and transplanted back into the body.[3]

Diagnostic Procedures[edit | edit source]

Multiple Myeloma Biopsy.jpg

According to the National Comprehensive Cancer Network (NCCN) criteria, MM is defined as smoldering (asymptomatic) or active (symptomatic). Major and minor criteria were created to distinguish multiple myeloma from asymptomatic myeloma and monoclonal gammopathies of undetermined significance (MGUS). 

  • The Evaluation of the patient is an involved process and beyond the scope of this article[3].
  • Diagnosis is not always obvious, especially in older patients, given their increased comorbidities. MM should always be suspected in an elderly patient with normocytic anemia, bone pain and evidence of renal dysfunction.

Prognosis[edit | edit source]

  • Older patients will often have serious concomitant diseases affecting survival.
  • Younger patients have less treatment-related morbidity, and consequently, fare better.
  • In 2003, with high-dose therapy followed by autologous stem cell transplantation, median survival was estimated to be approximately 4.5 years, compared to a median of approximately 3.5 years with standard therapy.
  • The overall survival in MM has improved over the last decade due to more accurate diagnosis and risk stratification, a better understanding of how toxicity and frailty can affect prognosis, the discovery of novel agents, and advances in supportive care during the post-transplant period.[3]
  • Overall, the 5-year survival rate is around 35%

Systemic Involvement[edit | edit source]

National-cancer-institute-0YBIMOqQzt0-unsplash.jpg

Immune System:

  • Recurrent bacterial infections (especially pneumococcal pneumonias)

Circulatory system:

  • Anemia with weakness and fatigue Bleeding tendencies

Skeletal System:

  • Bone destruction
    • Skeletal/bone pain (especially pelvis, spine and ribs)
    • Spontaneous fracture
    • Osteoporosis
    • Hypercalcemia (confusion, increased urination, loss of appetite, abdominal pain, vomiting, and constipation)

Urinary system:

  • Renal involvement
    • Kidney stones
    • Renal insufficiency

Neurological Systems:

  • Neurologic abnormalities
    • Carpal tunnel syndrome
    • Back pain with radicular symptoms
    • Spinal cord compression (motor or sensory loss, bowel/bladder dysfunction, paraplegia)[1]

Physical Therapy Management[edit | edit source]

Strengthing exercise for old people .jpg

Therapists can assist individuals with multiple myeloma to manage both the disease and treatment-related symptoms, improve overall quality of life, and prevent further complications associated with decreased activity and exercise. 

  • An important role in various stages of the progression of this disease includes prevention and management of: skeletal muscle wasting; cancer-related fatigue, and pathologic fractures. Exercise interventions to improve function and decrease muscle wasting and cancer-related fatigue during and after cancer treatment for multiple myeloma have been shown effective.[4]
  • Individualized exercise programs for individuals receiving aggressive treatment for multiple myeloma may be effective for decreasing fatigue and mood disturbance and for improving sleep. 
  • The guidelines suggest referral to physical therapy: Fitness assessment and exercise recommendations (emphasis on getting clients to gradually increase their activity level to avoid sustaining an injury or becoming discouraged). Short, low-intensity exercise programs may be helpful at first.
  • Implementation of a falls prevention programs can be a life-saving intervention for the individual at risk for pathologic fractures.[4]

Differential Diagnosis[edit | edit source]

Other conditions that can cause symptoms that may be confused with multiple myeloma that should be ruled-out include[5]:

  • Connective tissue disorders
  • Chronic infections
  • Skeletal (bone) metastases from cancers at other sites
  • Other causes of monoclonal gammopathy (increased levels of monoclonal antibodies) that include: Smoldering Multiple Myeloma, Solitary Plasmacytoma, Waldernstrom Macroglobulinemia, Plasma cell Leukemia (almost always associated with active multiple myeloma, Amyloidosis

Case Reports[edit | edit source]

Resources[edit | edit source]

References[edit | edit source]

  1. ↑ 1.0 1.1 1.2 3. Goodman C, Snyder T. Differential Diagnosis for Physical Therapists: Screening for Referral. St. Louis: Saunders Elsevier; 2007.
  2. ↑ American Cancer Society website. 2010. Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_2_1x_What_Is_Multiple_Myeloma.asp?sitearea=. Accessed April 4, 2010.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Albagoush SA, Azevedo AM. Cancer, Multiple Myeloma.Available from: https://www.ncbi.nlm.nih.gov/books/NBK534764/ (last accessed 14.7.2020)
  4. ↑ 4.0 4.1 Goodman C, Fuller K. Pathology: Implications for the Physical Therapist. St. Louis: Saunders Elsevier; 2009.
  5. ↑ MedifocusHealth.com 2007. Available at: http://www.medifocushealth.com/HM008/Diagnosis-of-Multiple Myeloma_Differential-Diagnosis-for-Multiple-Myeloma.php. Accessed April 4, 2010.
  6. ↑ Flodin U, Fredriksson M, and Persson B. Multiple myeloma and engine exhausts, fresh wood, and creosote: A case-referent study. American Journal of Industrial Medicine. Jan 2007. Volume 12; 5, 519-529.
  7. ↑ Eriksson M and Karlsson M. Occupational and other environmental factors and multiple myeloma: a population based case-control study. Br J Ind Med 1992;49:95-103.
  8. ↑ Alexander D, et. al. Multiple myeloma: A review of the epidemiologic literature. International Journal of Cancer. 2007. Volume 120; 12.
  9. ↑ Landgren O, et. al. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study. Int. J. Cancer. 2006. Volume 118, 3095–3098.
Retrieved from "https://www.physio-pedia.com/index.php?title=Multiple_Myeloma&oldid=316887"